USPTO Patents Application 10767824

PTO/SB/21 (03-03)
Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
;i?9^der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Ifbrmation unless It contains a valid OMB control

TRANSMITTAL
FORIM

fro be used for all correspondence after initial filing)

Appiicdtion Numbor

1 f\in^n Q1A
lU/ /o /,oZ4

Filing Date

January 29, 2004

First Named Inventor

Cooperstone et al

Group Art Unit

Examiner Name

5

Total Number of Pages in this Submission

Attorney Docl<et Number

AM-101305USA

ENCLOSURES (check all that apply)

n Fee Transmittal Form
Fee Attached
Amendment/Reply

After Final
□ Affidavits/declaration(s)
Extension of Time Request
Express Abandonment Request
Information Disclosure Statement

□
El

□

□

Certified Copy of Priority
Document(s)

Response to Missing Parts/
Incomplete Application

^ Response to Missing Parts
under 37 CFR 1.52 or 1.53,

□

Drawing(s)

n Licensing-related Papers

Petition

n Petition to Convert to a
Provisional Application

n Power of Attorney, Revocation

Change of Correspondence
Address

n Terminal Disclaimer
Request for Refund
n CD. Number of CD(s)

□
□
□

□
□
El

After Allowance Communication
to Group

Appeal Communication to Board
of Appeals and Interferences

Appeal Communication to Group

(Appeal NoUce, Brief, Reply Brief)

Proprietary Information
Status Letter

Other Enclosure(s) (please
identify below):

4-References

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm
or

Individual Name

HOWSON AND HOWSON
Cathy A. Kodroff

May 11, 2004

CERTIFICATE OF TRANSMISSION/MAILING

i hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient
postage as first class mail in an envelope addressed to: Commissioner for Patents. PO Box 1450, Alexandria, VA 22313*1450 on this date:

Typed or printed name

Signature

Date

This collection of information is required by 37 CFR 1.5. The inforniation is required to obtain or retain a benefit by the putMic wtilcti is to file (and t>y the USPTO to process) an
application. Conlidentiality is governed by 35 USC 122 and 37 CFR 1.14. Ttiis conection isestinr^ted to take 12 minutes to complete, including gathering, preparing, and submitting the
completed application form to the USPTO. Time will vary depending upon the individual case. Any connments on the amount of time you require to complete this form and/or
suggestions for reducing this burden, should b& sent to the Chief Information Officer. U.S. Patent and Trademad( Office. U.S. Department of Ccvnmeroe. Washington. DC 20231. OO
NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1 '800-PTO-9199 (1-800-786-9199) and select option 2,

Express Mail No. EU531571001US

Customer No. 38199

IN THE UNITED
Appln. No.

Applicant :

Filed :

Art Unit :

Examiner :

Customer No. :

Title :

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08 A/B document
listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B
is attached and a copy of the documents are enclosed herewith. This Information
Disclosure Statement is submitted after three months from the filing date of this
application and before the receipt of a first Office Action on the merits. Therefore, no
fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with
the filing of this paper or credit any overpayment in any fees to our Deposit Account
Number 08-3040.

EXPRESS MAIL NO. EU531571001US

AM-101305USA
STATES PATENT AND TRADEMARK OFFICE
10/767,824 Confirmation No. :

Cooperstone et al
January 29, 2004

38199

METHOD OF TREATING HEPATIC FIBROSIS

1

The Examiner is respectfully requested to consider the enclosed documents
identified in this paper and in the attached Form PTO/SB/08A/B during the coiu^e of
examination of this application.

Respectfully submitted,

HOWSON AlvfD HOWSON
Attorneys for Applicant

By

Cathy A. ^droff
Registration No. 33,980
Spring House Corporate Center
Box 457

Spring House, PA 19477
Phone: (215) 540-9200
Fax: (215) 540-5818

X9 t

PTO/SB/08B (08-00)
Approved for use through 4/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number

10/767,824

Filing Date

January 29, 2004

First Named Inventor

Cooperstone et al

Group Art Unit

Examiner Name

Sheet 1 of 2

Attorney Docket Number

AM-101305USA

U.S. PATENT DOCUMENTS

Examiner
Initials^

Cite
No.*

Document Number

Number-Kind Codc^*^""*^

Publication Date
MM-DD-YYYY

Name of Patentee or
Applicant of Cited
Document

Pages, Columns, Lines, Where
Relevant Passages or Relevant
Figures Appear

DD

5,665,772

09-09-1997

Cottens et al

FOREIGN PATENT DOCUMENTS

Examiner
Initials*

Cite
No.^

Foreign Patent Document

Country Code'- Number*-Klnd Co6e^of known)

Publication Date
MM-DD-YYYY

Name of Patentee
or Applicant of
ated Document

Pages, Columns,
Lines, Where
Relevant Passages or

Relevant Figures
Appear

Examiner
Signature

Date

Considered

* EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance
and not considered. Include copy of this form with next communication to applicant. ^ Applicant's unique citation designation number (optional). ^ See
Kinds Codes of USPTO Patent Documents at www.uspto.oov or MPEP 901.04. ^ Enter Office that issued the document, by the two-letter code (WIPO
Standard ST. 3). ** For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent
document. ^ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ^Applicant is to place
a checl< marl< here If English language Translation Is attached.

This collection of Information is required by 37 CFR 1.97 and 1,98. The Information is required to obtain or retain a benefit by the public which Is to flie
(and by the USPTO to process) an application. Confidentiality Is governed by 35 USC 122 and 37 CFR 1.14. this collection Is estimated to talce 2 hours
to complete, Including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the
Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent
to the Chief Information Officer, U.S. Patent and Trademaric Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR

3

PTO/SB/08B (08-00)
Approved for use through 4/30/2003. 0MB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid 0MB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number

10/767,824

Filing Date

January 29, 2004

First Named Inventor

Cooperstone et al

Group Art Unit

Examiner Name

Sheet 2 of 2

Attorney Docket Number

AM-101305USA

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS

Examiner
Initials*

Cite
No.'

Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of
the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), columeousse
number(s), publisher, city and/or country where published

T^

EE

SHIBATA ET AL, Establishment of an Immortalized Human Hepatic Stellate Cell Line to
Develop Antifibrotic Therapies, Cell Transplantation, Vol. 12, pp. 499-507, (2003)

FF

FRIEDMAN ET AL, The Virtuosity of Hepatic Stellate Cells, Gastroenterology, Vol. 1 17,
No. 5, pp. 1244-1246, (November 1999)

*

GG

ZHU ET AL, Rapamycin Inhibits Hepatic Stellate Cell Proliferation in Vitro and Limits
Fibrogenesis in an In Vivo Model of Liver Fibrosis, Gastroenterology 1 17, 5, pp. 1 198-1204,
(November 1999)

Examiner

Date

Signature

Considered

* EXAMINER: Initial If reference considered, whether or not citation is In conformance with MPEP 609. Draw line through citation if not in conformance
and not considered. Include copy of this form with next communication to applicant.

^ Appiicant's unique citation designation number (optionai). ^Applicant Is to place a checic mark here If English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which Is to file
(and by the USPTO to process) an application. Confidentiality Is governed by 35 USC 122 and 37 CFR 1.14. this collection Is estimated to take 2 hours
to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the
Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent
to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR
COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in compieting the form, cali 1-800'PTO-9199 (1-800-786-9199) and select option 2,

4